Pharmacoeconomic analysis of antibiotic therapy in surgical site infections

Abstract

Objective: Surgical site infections (SSIs) are considered to be one of the most common complications in operative treatment due to increased microbiological resistance. Having knowledge of the flora that most frequently cause SSIs in a given population allows for the implementation of effective empirical antibiotic therapies. Such an approach leads to a decrease in both time and costs associated with SSI treatment. The aim of this paper is to assess the most common pathogens causing SSIs in orthopedic and general surgery and to conduct a cost-minimization analysis.

Materials and methods: A total of 908 isolates from 547 patients with an SSI in general surgery and 463 swabs from 267 patients with an SSI at the department of orthopedics were obtained. All patients were treated at St. John of God Hospital in Katowice from 2011 to 2016.

Results: The incidence rate of SSIs was 4.25% in general surgery and 2.66% in orthopedics. The most commonly isolated strains in general surgery were E. coli (24.3%), K. pneumoniae (12.5%), and P. mirabilis (4.76%). Gram-positive cocci dominated the isolates in orthopedics, with S. epidermidis and S. aureus accounting for 19.8% and 13.6%, respectively. The most cost-effective antibiotics for general surgery are currently the cephalosporins cefotaxime or ceftriaxone, either alone or in combination with amikacin, while in orthopedics the most cost-effective were trimethoprim/sulfamethoxazole.

Conclusion: Empirical antibiotic therapy should be based on the current epidemiological situation of infections from both a medical and pharmacoeconomic point of view.